Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Inflammation of the pars plana.
Biomarker and diagnostic research for intermediate uveitis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 2 PHASE3. Research is sponsored by a mix of industry and academic institutions.
176 publications have been identified in PubMed for intermediate uveitis. Research spans Epidemiology / Natural History (35%), Case Report / Case Series (32%), and Review / Meta-Analysis (12%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 51 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 4:28 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies | 47 | 32% |
Research summaries | 18 | 12% |
Clinical study results | 16 | 11% |
Testing and diagnosis research | 7 | 5% |
Laboratory research | 3 | 2% |
New treatment approaches | 3 | 2% |
Other research | 1 | 1% |
Sharma A (2026). [PMID: 41835310](https://pubmed.ncbi.nlm.nih.gov/41835310/). *Case Rep Ophthalmol*. [Case Report / Case Series]
Kritika (2026). [PMID: 41710171](https://pubmed.ncbi.nlm.nih.gov/41710171/). *Clin Ophthalmol*. [Epidemiology / Natural History]
Barbosa LIT (2026). [PMID: 41546697](https://pubmed.ncbi.nlm.nih.gov/41546697/). *Graefes Arch Clin Exp Ophthalmol*. [Review / Meta-Analysis]
Kötter I (2026). [PMID: 42155459](https://pubmed.ncbi.nlm.nih.gov/42155459/). *Klin Monbl Augenheilkd*. [Review / Meta-Analysis]
Cieślik M (2026). [PMID: 41994897](https://pubmed.ncbi.nlm.nih.gov/41994897/). *Ocul Immunol Inflamm*. [Review / Meta-Analysis]
Shoughy S (2026). [PMID: 42153941](https://pubmed.ncbi.nlm.nih.gov/42153941/). *Ocul Immunol Inflamm*. [Epidemiology / Natural History]
Schneider M (2026). [PMID: 42141825](https://pubmed.ncbi.nlm.nih.gov/42141825/). *Acta Ophthalmol*. [Epidemiology / Natural History]
Abdullatif AM (2026). [PMID: 41417954](https://pubmed.ncbi.nlm.nih.gov/41417954/). *Ocul Immunol Inflamm*. [Epidemiology / Natural History]
Nguyen RD (2026). [PMID: 39804108](https://pubmed.ncbi.nlm.nih.gov/39804108/). *Ocul Immunol Inflamm*. [Case Report / Case Series]
Mäkelä HM (2026). [PMID: 42030885](https://pubmed.ncbi.nlm.nih.gov/42030885/). *Mult Scler Relat Disord*. [Epidemiology / Natural History]
AI-curated news mentioning intermediate uveitis
Updated Aug 30, 2026
A study published on PubMed examines the clinical profile of uveitis in leprosy patients in Egypt, providing insights into the ocular complications associated with the disease. This research contributes to the understanding of leprosy-related conditions and their management.
Regeneron has discontinued a clinical study for an antibody targeting uveitis due to an unfavorable risk/benefit profile. This decision follows recent Phase 3 failures of itepekimab and a combination regimen for melanoma.
Regeneron has discontinued a clinical study for an antibody targeting uveitis due to safety concerns. This decision follows recent Phase 3 failures of itepekimab and a combination regimen for melanoma.
A recent study explores the characteristics of uveitis associated with juvenile idiopathic arthritis (JIA) during the transition age. The findings may provide insights into managing this condition in young patients.
A case report highlights the occurrence of herpes simplex virus type 1 uveitis in the fellow eye following intravitreal administration of bevacizumab. This finding may prompt further investigation into the safety profile of bevacizumab in patients with a history of herpes virus infections.